Abstract
In metastatic breast cancer (MBC) the combination of Bevacizumab (Avastin) and chemotherapy (CT) failed to demonstrate an increase in overall survival with a significant improvement of the objective response rate and progression-free survival (PFS) in randomized trials of the 3d phase. Nevertheless, observational studies in the daily clinical practice for the use of Bevacizumab in MBC continue in the world. We present the results of our own observational study, which goal is to assess the efficacy and tolerability of Bevacizumab in combination with CT in patients with HER/2-negative metastatic and locally advanced breast cancer. The study included 34 patients with breast cancer (6-locally advanced, 28-metastatic) at the age of 29 to 66 years (mean – 49.5). Bevacizumab was administered at a dose of 7.5 to 15 mg/kg every 3 weeks in combination with CT. In total, the patients received 294 doses of Bevacizumab (median – 10). All patients with locally advanced breast cancer were operated on after the treatment completion, a pathologic complete response was registered in 33.3%. In MBC, the objective response was registered in 46,4%, tumor growth control in 89.3%, median PFS – 10 months. Typical for Bevacizumab adverse events, such as hypertension, proteinuria, were moderate and were met respectively in 14.7% and in 5.9% cases. In 1 (2.9%) patient the treatment was complicated by deep vein thrombosis and PE due to disease progression. Conclusion. Bevacizumab in combination with CT in breast cancer treatment can achieve high rates of objective response and PFS independent of the treatment line
Highlights
Observational studies in the daily clinical practice for the use of Bevacizumab in metastatic breast cancer (MBC) continue in the world
We present the results of our own observational study, which goal is to assess the efficacy and tolerability of Bevacizumab in combination with CT in patients with HER / 2‐negative metastatic and locally advanced breast cancer
Bevacizumab was administered at a dose of 7.5 to 15 mg / kg every 3 weeks in combination with CT
Summary
Резюме: Бевацизумаб (Авастин) в комбинации с химиотерапией (ХТ) 1–2‐й линий при метастатическом раке молочной железы (мРМЖ) в рандомизированных исследованиях III фазы не продемонстрировал увеличения общей выживаемости (ОВ) при значимом повышении частоты объективного ответа и выживаемости без прогрессирования (ВБП). Что в трех крупных рандомизированных исследованиях III фазы Бевацизумаб в сочетании с химиотерапией (ХТ) 1–2‐й линий, несмотря на значимое увеличение выживаемости без прогрессирования (ВБП) и частоты объективного ответа, не продемонстрировал увеличения общей выживаемости (ОВ). В рандомизированном исследовании III фазы RIBBON-2 во 2‐й линии лечения мРМЖ добавление Бевацизумаба к ХТ также продемонстрировало статистически значимое увеличение частоты объективного ответа с 29,6 % до 39,5 % (р=0,0193) и медианы ВБП с 5,1 до 7,2 мес. В отделении амбулаторной химиотерапии РОНЦ проводится наблюдательное исследование, целью которого является оценка переносимости и эффективности Бевацизумаба в комбинации с химиотерапией (ХТ) у больных HER / 2‐негативным диссеминированным и местно-распространенным раком молочной железы в рамках ежедневной клинической практики. В данной работе приводятся результаты, полученные за период с 2008 по 2015 год
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
